Pfizer

PowerShares S&P SmallCap Health Care (NYSE: PSCH) is up nearly 22% year to date. The investment seeks to replicate the S&P SmallCap 600 Capped Health Care index, which is comprised of common stocks of U.S. health care companies. Top holdings include Regeneron Pharmaceuticals (NASDAQ: REGN...

First Trust Consumer Staples AlphaDEX (NYSE: FXG) is up more than 20% year to date. The investment seeks results that correspond generally to the price and yield of an equity index called the StrataQuant Consumer Staples Index. Top holdings include Green Mountain Coffee Roasters (NASDAQ: GMCR),...

Morgan Stanley reiterated its Overweight rating on Pfizer (NYSE: PFE). At the same time, the rating agency decided to leave its price target on the company's stock unchanged at $22. On Thursday, Pfizer ended the day at $20.65. Its shares lost 0.44% in today's pre-market trading to trade around $20....

Bank of America Merrill Lynch is out with its report today on Pfizer (NYSE: PFE), maintaining Buy. In a note to clients, Bank of America Merrill Lynch writes, "Pfizer offers compelling valuation, an attractive dividend yield, and the potential for the ongoing strategic review to lead to actions...

  MAKING THE VALUE PROPOSITION FOR STAR SCIENTIFIC Tobacco could kill one billion people this century -(Reuters) Part one: CigRx™, the over-the-counter nutraceutical that reduces the urge to smoke. My recent reports on Star Scientific have dealt largely with...

The U.S.-Russia Business Council Board Members, led by USRBC Chairman Klaus Kleinfeld of Alcoa, met today with President Medvedev in St. Petersburg at The St. Petersburg International Economic Forum to present him with a letter voicing their full support for the Russian Federation's accession to...

Pfizer Inc. (NYSE: PFE) summarized its oncology pipeline at an investor meeting at the American Society of Clinical Oncology (ASCO) meeting in Chicago last evening, Citi reports. “PFE reviewed data presented on late-stage products including crizotinib, axitinib & bosutinib,” Citi writes. “PFE...

J.P. Morgan provided color on Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). In a research report published today, J.P. Morgan commented on the companies' new drugs. J.P. Morgan is more impressed by Pfizer at the moment. In the report, J.P. Morgan states on BMY's Yervoy, "meaningful...

According to Citi, Pfizer (NYSE: PFE) price target is $23. Citi said that it arrives at its $23 target price for Pfizer based on a relative P/E compared to the US Drug peer group. “We assume PFE trades at ~10x our 2012E EPS of $2.29, or roughly in-line with its peers. Although PFE's growth...

Bank of America reiterated its Buy rating on Pfizer (NYSE: PFE). In a research report published today, Bank of America states, "Pfizer offers compelling valuation, an attractive dividend yield, and the potential for the ongoing strategic review to lead to actions that could enhance shareholder...

Jefferies is providing some comments on Pfizer's (NYSE: PFE) JAK inhibitor, tofacitinib. “Oral targeted disease modifying Rheumatoid Arthritis (RA) treatments were the hot topic at this year's European League Against Rheumatism (EULAR) annual meeting, last week (May 25-28),” Jefferies writes. “...

Citi is out with its report today on Pfizer (NYSE: PFE), maintaining High Risk. In a note to clients, Citi writes, ".We rate Pfizer shares High Risk given the continued deterioration of its base business in the US, execution risk on the pipeline, and potential restructuring issues. Additional...

Citigroup has raised the price target on Pfizer (NYSE: PFE) from $20 to $23 and maintains its Hold rating.

Goldman Sachs is out with its report today on Pfizer (NYSE: PFE), maintaining Buy. In a note to clients, Goldman Sachs writes, "We remain confident that PFE's Ian Read will move rapidly to pare the business through break-ups/spins, and expect more granularity with respect to timing on the call....

Jefferies is out with its "Life Sciences & Diagnostics" update today, discussing R&D spending growth. In a note to clients, Jefferies writes, "Based on the most recent forecasts of Jefferies' Global Healthcare team, we are lowering our 2011 core commercial R&D spending growth forecast...